EUVIMEDEUVIMED entdecken
Crossref

Are Genetics Useful to Guide Ablation Strategies in Patients With Persistent Atrial Fibrillation?

Michael W Lim iD, Peter M Kistler iD, Annie G Curtin, David Chieng, Jeremy William, Louise Segan, Rose Crowley, Magdalena J Soka, Paul E Young, Emma M Rath, Chenglong Yu, Monique Ohanian und 8 weitere

Journal of Cardiovascular Electrophysiology · 2026-05 · 37 (5) · 917-924

DOI: 10.1111/jce.70297 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cardiovascular Electrophysiology, online erschienen am 04.03.2026. Verfasst von Michael W Lim und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Royal Melbourne Hospital, Parkville, Victoria, Australia. Hauptthemen laut MEDLINE: Atrial Fibrillation, Catheter Ablation, Pulmonary Veins, Heart Rate. Die Arbeit nennt 22 Literaturangaben. Gefördert von: the National Heart Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In the CAPLA trial, arrhythmia‐free survival did not differ between patients with persistent atrial fibrillation (AF) who underwent pulmonary vein isolation (PVI) with posterior wall isolation (PWI) vs. PVI alone. High AF polygenic risk scores (PRS) have been associated with increased left atrial substrate and arrhythmia recurrence post‐ablation. Whether AF patients with high AF‐PRS benefit from a more extensive ablation strategy (PVI with PWI) is unknown.

Objective

To investigate the impact of adjunctive PWI on ablation outcomes in patients with persistent AF stratified by AF‐PRS.

Methods

Genome‐wide genotyping was performed in a CAPLA trial subgroup and a previously validated AF‐PRS was derived. The primary endpoint was freedom from documented atrial arrhythmia with or without the use of antiarrhythmic drugs at 3 years after a single ablation procedure in patients with high AF‐PRS who underwent PVI with PWI vs. PVI alone.

Results

One hundred and seventy‐four patients (75.29% male, median age 66.70 years) were evaluated. Mean AF‐PRS was significantly higher than in a control cohort of healthy individuals (30.23 vs. 30.15; p < 0.001). Amongst patients with high AF‐PRS (defined by AF‐PRS corresponding to the top quartile of control cohort scores), there were no significant differences between patients who underwent PVI with PWI ( n = 36) vs. PVI only ( n = 49) with respect to atrial arrhythmia‐free survival ( p = 0.883), arrhythmia burden ( p = 0.772) or quality‐of‐life scores ( p = 0.794) over median follow‐up of 3.76 years.

Conclusion

In patients with persistent AF undergoing ablation, the addition of PWI to PVI in those with high AF‐PRS did not significantly improve long‐term ablation outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationCatheter AblationPulmonary VeinsHeart RateHumansMaleFemaleGenetic Risk ScoreMiddle AgedAgedGenetic Predisposition to DiseaseTime FactorsRisk FactorsRisk AssessmentProgression-Free SurvivalTreatment OutcomePhenotypeAction PotentialsPredictive Value of TestsRecurrenceGenome-Wide Association StudyAnti-Arrhythmia AgentsClinical Decision-Making

Stichwörter der Autor:innen

persistent atrial fibrillationpolygenic risk scoreposterior wall isolation

Substanzen

Anti-Arrhythmia Agents

Autor:innen und Institutionen

  • Department of Cardiology, Royal Melbourne Hospital, Parkville, Victoria, Australia.
  • Heart Centre, The Alfred Hospital, Melbourne, Victoria, Australia.
  • Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia.
  • Baker Heart and Diabetes Research Institute, Melbourne, Victoria, Australia.
  • Victor Chang Cardiac Research Institute, Darlinghurst, New South Wales, Australia.
  • Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.

ORCID-Profile: Michael W Lim, Peter M Kistler, Paul Lacaze, Jonathan M Kalman

Förderung

  • the National Heart Foundation

Zitieren

APA

Lim, M. W., Kistler, P. M., Curtin, A. G., Chieng, D., William, J., Segan, L., Crowley, R., Soka, M. J., Young, P. E., Rath, E. M., Yu, C., Ohanian, M., Johnson, R., Lacaze, P., Giannoulatou, E., Voskoboinik, A., Prabhu, S., Sugumar, H., Fatkin, D., & Kalman, J. M. (2026). Are Genetics Useful to Guide Ablation Strategies in Patients With Persistent Atrial Fibrillation?. Journal of Cardiovascular Electrophysiology, 37(5), 917-924. https://doi.org/10.1111/jce.70297

Vancouver

Lim MW, Kistler PM, Curtin AG, Chieng D, William J, Segan L, et al. Are Genetics Useful to Guide Ablation Strategies in Patients With Persistent Atrial Fibrillation?. Journal of Cardiovascular Electrophysiology. 2026;37(5):917-924. doi:10.1111/jce.70297

BibTeX
@article{Lim2026,
  author = {Lim, Michael W and Kistler, Peter M and Curtin, Annie G and Chieng, David and William, Jeremy and Segan, Louise and Crowley, Rose and Soka, Magdalena J and Young, Paul E and Rath, Emma M and Yu, Chenglong and Ohanian, Monique and Johnson, Renee and Lacaze, Paul and Giannoulatou, Eleni and Voskoboinik, Aleksandr and Prabhu, Sandeep and Sugumar, Hariharan and Fatkin, Diane and Kalman, Jonathan M},
  title = {Are Genetics Useful to Guide Ablation Strategies in Patients With Persistent Atrial Fibrillation?},
  journal = {Journal of Cardiovascular Electrophysiology},
  year = {2026},
  volume = {37},
  number = {5},
  pages = {917--924},
  doi = {10.1111/jce.70297}
}
Kostenlos starten →